Syapse, a a San Francisco, CA-based provider of precision oncology solutions, has raised $30 million in Series D financing. Participants include existing investors Ascension Ventures, GE Ventures, Intermountain Healthcare Innovation Fund, Safeguard Scientifics, and Social Capital, as well as new investors Amgen Ventures, Medidata Solutions, Merck Global Health Innovation Fund, and Roche Venture Fund.The company plans to use the latest round of funding to expand operations and bring its precision
Read More
Precision Medicine Oncology | Molecular Profiling | News, Analysis, Insights
Tempus, Cleveland Clinic Collaborate on Personalized Cancer Medicine Initiative
Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and Cleveland Clinic Taussig Cancer Institute will collaborate on a precision medicine initiative aimed at improving outcomes for patients diagnosed with cancer.As part of the research collaboration spanning multiple cancer subtypes, Tempus will provide molecular sequencing and analysis for patients enrolled in a precision oncology clinical
Read More
Quest Diagnostics Completes Acquisition of Med Fusion
Quest Diagnostics has announced the completed its acquisition of the laboratory businesses Med Fusion and Clear Point. Operating from a nearly 200,000 square foot facility in Lewisville, Texas, the two businesses form the basis for the company’s first national center of excellence in precision diagnostics for oncology. For patients with cancer, precision diagnostics, such as genomic sequencing of a tumor's DNA, may help a physician select a therapy or clinical trial and monitor response.In
Read More
Northwestern, Tempus Expand Partnership to Accelerate Personalizing Care for Cancer Patients
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University is expanding its partnership with Tempus aimed at personalizing care for cancer patients. Tempus provides molecular sequencing and clinical analytic solutions for top academic centers, hospital systems, associations, and healthcare providers.As part of the expanded collaboration, Tempus will provide molecular sequencing and analysis for patient derived xenograft (PDX) models and patient derived organoid models, which will
Read More
Aurora Cancer Care Launches Precision Medicine Program To Help Patients Gain More Access to Clinical Trials
Aurora Cancer Care, a not-for-profit health care provider in Wisconsin and northern Illinois is launching a precision medicine program powered by Syapse, a provider of precision oncology solutions. The new oncology precision medicine program will help physicians and researchers provide more care options for patients whose cancer is resistant to conventional treatment options like radiation and chemotherapy.The new multi-disciplinary Oncology Precision Medicine Clinic will be located inside
Read More
University of Miami Health to Launch New Precision Medicine Initiative for Personalized Cancer Care
Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, announced today is it partnering with Syapse to launch a scalable precision medicine initiative that will benefit thousands of cancer patients in South Florida and improve survival rates. The partnership with Syapse will enable doctors at UMiami’s Sylvester Comprehensive Cancer Center to deliver personalized care that matches patients with targeted, cutting-edge cancer therapies, resulting in better
Read More
N-of-One Raises $7M for Precision Medicine Oncology Decision Support
N-of-One, a precision medicine oncology decision support company has raised $7 million in funding from Providence Ventures and Excel Venture Management. The latest round brings its total funding to $11M. Founded in 2008 by a team of PhD scientists and oncologists, N-of-One analyzes and interprets tumor molecular profiles to help physicians and patients identify diagnostic and treatment strategies from its proprietary database.Working with leading healthcare systems and large commercial labs,
Read More
